SIGHT SCIENCES, INC.

Insiders Sight Sciences, Inc.

Equities

SGHT

US82657M1053

Market Closed - Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
6.19 ^USD	+0.49%		+1.73%	+19.96%

May. 28	Sight Sciences Trial Results Show Improved Dry Eye Disease Signs, Symptoms for TearCare Patients Crossed Over From Restasis	MT
May. 28	Sight Sciences, Inc. Announces Publication of New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with Omni®? Across Mild, Moderate, and Advanced Glaucoma	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sight Sciences, Inc. Appoints Matthew Link as Chief Commercial Officer	23-09-11	CI
Sight Sciences Announces Appointment of Catherine Mazzacco as New Director	23-06-12	CI
Sight Sciences, Inc. Announces Board Changes	23-04-26	CI
Sight Sciences Names Alison Bauerlein Chief Financial Officer	23-04-03	MT
Sight Sciences Expects 40% Year-Over-Year Rise in Q4 2022 Revenue; Chief Financial Officer Steps Down	23-01-10	MT
Sight Sciences, Inc. Announces Executive Changes	23-01-09	CI
Sight Sciences, Inc. Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors	22-07-19	CI
Sight Sciences Appoints Brenda Becker to Its Board of Directors	22-03-16	CI
Sight Sciences, Inc. Announces the Resignation of Andrew Offer from Class I Director of the Board of Directors	22-03-04	CI
Insider Buy: Sight Sciences	21-12-02	MT
Insider Buy: Sight Sciences	21-10-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer